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Abstract 
Allergy immunotherapy (AIT) is acknowledged to produce beneficial mid- and long-term clinical and immunologic 
effects and increased quality of life in patients with allergic respiratory diseases (such as allergic rhinoconjunctivitis 
and allergic asthma). However, poor adherence to AIT (due to intentional and/or non-intentional factors) is still a bar-
rier to achieving these benefits. There is an urgent need for patient support programs (PSPs) that encompass com-
munication, educational and motivational components. In the field of AIT, a PSP should be capable of (1) improving 
adherence, (2) boosting patient engagement, (3) explaining how AIT differs from pharmacological allergy treatments; 
(4) increasing health literacy about chronic, progressive, immunoglobulin-E-mediated immune diseases, (5) helping 
the patient to understand and manage local or systemic adverse events, and (6) providing and/or predicting local 
data on aeroallergen levels. We reviewed the literature in this field and have identified a number of practical issues to 
be addressed when implementing a PSP for AIT: the measurement of adherence, the choice of technologies, remind-
ers, communication channels and content, the use of “push” messaging and social networks, interactivity, and the 
involvement of caregivers and patient leaders. A key issue is “hi-tech” (i.e. approaches based mainly on information 
technology) vs. “hi-touch” (based mainly on interaction with humans, i.e. family members, patient mentors and health-
care professionals). We conclude that multistakeholder PSPs (combining patient-, provider and society-based actions) 
must now be developed and tested with a view to increasing adherence, efficacy and safety in the field of AIT.
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Background
Allergy immunotherapy (AIT, either sublingual or sub-
cutaneous) is acknowledged to have beneficial mid- and 
long-term clinical and immunologic effects on patients 
with allergic respiratory diseases (such as allergic rhino-
conjunctivitis and allergic asthma). In particular, those 
effects may persist for several years after discontinuation 
[1–4]. Indeed, long-term efficacy and sustained (post-
treatment) efficacy are important parameters in the regu-
latory approval of AIT formulations in Europe [5]. Even 
though AIT has a relatively short (intra-season) onset 
of action [6] for symptom relief, multi-season or multi-
year administration of AIT is required to achieve a long-
lasting, disease-modifying effects. Poor adherence to 
long-term AIT (as with other chronic treatments) is thus 
a barrier to obtaining allergen tolerance, symptom relief 
and improved quality of life (QoL).
Review
Adherence to long‑term treatment: a key reason for trying 
to boost patient engagement
Although progress in technology and medicine offers great 
opportunities for healthy living, successful outcomes are 
increasingly reliant on the patient’s active participation in 
his/her treatment. However, one of the main problems in 
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modern medicine—especially in the field of chronic dis-
ease—is patient adherence, defined by the World Health 
Organization as “the extent to which a person’s behavior—
taking a medication, following a diet or executing lifestyle 
changes—corresponds with agreed recommendations from 
a healthcare provider” [7]. In a quote attributed to the for-
mer US Surgeon General Dr. C. Everett Koop, “drugs don’t 
work in patients who don’t take them”.
Adherence can be broken down into several stages 
(Fig.  1): (1) initiation (also referred to as acceptance), (2) 
implementation (also referred to as compliance, i.e. the 
proportion of the recommended doses of medication 
actually taken by the patient) and (3) persistence (i.e. not 
discontinuing the treatment before the end of the recom-
mended period) [7–9]. There are many intentional or non-
intentional reasons why a patient may fail to take his/her 
medication or not follow other healthcare measures pre-
scribed by a physician (Table  1) [10, 11]. However, most 
(but not all) studies of non-adherence in chronic disease 
suggest that non-intentional reasons predominate—mainly 
“I simply forgot” and variants of the latter [12, 13]. In inten-
tional non-adherence, patients often irrationally consider 
that the risks associated with adherence are greater than 
the risks associated with non-adherence (Table 1).
Levels of adherence in patients on AIT
It has been estimated that the compliance rate for drug 
therapy of chronic disease is barely over 50 % [7]; most of 
these data have come from studies of patients with dia-
betes, chronic kidney disease, neurologic disorders, car-
diovascular disease or AIDS. In the literature on AIT, the 
compliance component of adherence ranges from around 
25 % to over 90 % [14]. In a recent Italian study of sales 
data provided by two major manufacturers, more than 
50  % of patients discontinued sublingual allergy immu-
notherapy (SLIT) during the first year, and only 13  % 
were still on treatment in the second year. This short-
fall was independent of the allergen source, administra-
tion regimen and, in part, reimbursement status [15]. A 
German retrospective analysis of renewal rates for grass 
pollen AIT found that 49 and 64  % of patients did not 
renew their SLIT or SCIT prescription, respectively, over 
2 years [16]. Hence, increasing the adherence rate may be 
an important way of improving safety, efficacy, quality of 
life (QoL) and other patient-related outcomes in AIT.
Key factors in improving adherence rates
A multitude of organizational, educational and techno-
logical interventions have been developed or proposed 
with a view to improving adherence and patient out-
comes. In a Cochrane review, Haynes et al. [17] reported 
that only 26 out of 58 interventions in 49 randomized 
clinical trials were associated with improved adherence, 
and that almost all of the interventions with long-term 
efficacy were complex and multifactorial. Furthermore, it 
appears to be impossible to predict which interventions 
will or will not work in a particular setting and over a 
given timeframe. Behavioral interventions for enhancing 
medication adherence (when behavioral counselling is 
directly offered to patients by specifically trained health 
care professionals) have shown contradictory results [18]. 
Unfortunately, even the most successful interventions did 
not produce large improvements in adherence.
Patient education, health literacy, patient-centered 
care, patient-centered communication, patient activa-
tion and patient engagement are related but non-identi-
cal approaches that can potentially improve adherence. 
Firstly, patient education has been variously defined as 
“any set of planned educational activities designed to 
improve patients’ health behaviors and health status” 
[19] and “a process of assisting consumers of health care 
to learn how to incorporate health-related behaviors (i.e., 
knowledge, skills and/or attitudes) into everyday life with 
the purpose of achieving the goal of optimal health” [20]. 
Secondly, health literacy is defined by the US Institute 
of Medicine of the National Academies as “the degree to 
which individuals have the capacity to obtain, process, 
and understand basic health information needed to make 
appropriate health decisions” [21]. Low health literacy is 
associated with poor adherence and poor outcomes [22–
24]. However, most programs based on health educa-
tion, information, literacy or numeracy alone have failed 
to improve adherence, even though they do improve the 
level of knowledge about disease [16, 25].
Fig. 1 A schematic diagram of the components of adherence. Adapted from [6–8]
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Lastly, patient engagement—described as “the block-
buster drug of the century” [26]—has been defined as 
“actions [that] individuals must make to obtain the 
greatest benefit from the health care services available to 
them” by the Center for Advancing Health [27] and “the 
involvement in their own care by individuals (and others 
they designate to engage on their behalf ), with the goal 
that they make competent, well-informed decisions about 
their health and health care and take action to support 
those decisions” by the Agency for Healthcare Research 
and Quality [28]. Both these definitions emphasize that 
even a well-informed, health-literate patient must also 
be personally committed, motivated and pro-active if he/
she is to help prevent, manage and treat his/her disease. 
It has been reported that in patients with chronic meta-
bolic diseases, empowerment-based self-management 
interventions have stronger, long-lasting effects than 
conventional self-management or education, although 
adherence has not always been assessed in these studies 
[29–31]. Furthermore, the time that healthcare profes-
sionals can dedicate to allergic patients (and their par-
ents, when considering pediatric patients) in the office 
may modulate the above-mentioned educational and 
psychological factors. For example, Rolinck-Werninghaus 
Table 1 Barriers to good adherence and patient engagement [6–14] and the corresponding interventions
Factors in poor adherence and examples Interventions for patient support programs
Intentional factors
Fear and experience of side effects
The patient has experienced or fears experiencing side effects and thus avoids 
taking the medication
Explanation and coaching by healthcare professionals (patient empower-
ment)
Collaborative care and raised awareness of AIT
Lack of perceived efficacy
The patient considers that the medication is not “working” and is of no value
Individual patient coaching
Explanation and coaching by healthcare professionals (patient empower-
ment)
Collaborative care and raised awareness of AIT
High perceived efficacy
The patient considers that the medication has done its job and can thus be 
discontinued
Individual patient coaching
Coaching by healthcare professionals (patient empowerment)
Collaborative care and raised awareness of AIT
Financial issues
The patient considers that he/she can save money by reducing the number of 
doses or the duration of treatment
Point-of-care cost reduction
Social issues and lack of convenience
The patient is embarrassed to take his/her medication when outside the home 
setting (for AIT normally administered at home) or fails to renew or collect a 
prescription due to travel/cost issues
Easy-to-administer formulations
Patient mentors
Explanation and coaching by healthcare professionals (patient empower-
ment)
Psychological factors
The patient does not accept that he/she is really ill (denial of the disease), and 
so not taking the medication helps him/her to think less about the disease
Explanation and coaching by healthcare professionals (patient empower-
ment)
Collaborative care and raised awareness of AIT
Non-intentional factors
Forgetfulness
The patient forgets to take his/her medication. Forgetfulness can be accentu-
ated by a number of lifestyle and health-related factors (travel, age, co-
morbidities, social activities etc.)
Reminders sent by: telephone (automated or human), text messages, 
e-mail, social networks, electronic pillboxes.
Patient mentors
Individual patient counselling
Poor physician-patient communication and/or poor health literacy
The patient does not understand the dosing instructions and/or does not how 
to resume treatment after interruption
Clearer product information sheets
Simplified but safe regimens for resumption after interruption
Patient mentors
Explanation and coaching by healthcare professionals (patient empower-
ment)
Collaborative care and raised awareness of AIT
Unscheduled travel or school/work commitments
The patient has to travel or change his/her daily routine unexpectedly, which 
interferes with taking medication
Easy-to-administer formulations
Reminders sent by: telephone (automated or human), text messages, 
e-mail, social networks, electronic pillboxes
Poor stock management
The patient fails to anticipate the need to renew a prescription and therefore 
runs out of medication
Reminders sent by: telephone (automated or human), text messages, 
e-mail, social networks, electronic pillboxes
Individual patient coaching
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et  al. [32] reported that an individually tailored nurse 
consultation for parents of children with atopic derma-
titis was associated with significant benefits in terms of 
reduced disease severity and confidence in dealing with 
the disease. Group educational programs were particu-
larly effective in parents with poor coping abilities at 
baseline [33].
Patient engagement and patient support programs (PSPs) 
in the field of respiratory allergies and AIT
Patient engagement must be kindled and maintained. 
PSPs (including communication, educational and moti-
vational components) are intended to boost patient 
engagement, improve adherence (initiation, compliance 
and persistence), help patients understand and manage 
their disease, improve QoL and facilitate patient-physi-
cian communication, concordance and trust.
In the field of AIT, a PSP will have additional, specific 
objectives:
 – Explain the benefits of AIT and how it differs from 
other allergy treatments: the disease-modifying mode 
of action vs. symptomatic medication, short- and 
long-term benefits of AIT, modes of administration, 
the recommended duration of treatment (3–5  years), 
the onset of action of AIT (as early as the first season, 
within 1–4 months of initiation [6]), reduction in the 
need for pharmacotherapy, and possible prevention of 
the progression of the allergic disease such as second-
ary/tertiary prevention regarding the development of 
asthma [4, 34].
  – Increase health literacy about allergic disease (from 
the diagnosis onwards, if possible), with a focus on 
chronic, progressive, immunoglobulin-E-mediated 
immune diseases with health, work and QoL conse-
quences.
  – Help to understand and manage local or systemic 
adverse events and those related to the administration 
route, whether SLIT or subcutaneous allergy immuno-
therapy (SCIT).
  – Improve adherence year after year or season after sea-
son, in order to obtain the disease-modifying benefits 
of AIT.
 – Provide data on and/or predict aeroallergen and pol-
lutant levels on a local basis (for a patient’s place of res-
idence or when travelling), with customized alerts for 
specified allergen sources. This is essential in pollen-
induced allergies, due to the well-known variability of 
pollen seasons as a function of geographic location and 
climate. Prediction of the start of a pollen season is less 
useful in patients following a perennial AIT regimen or 
a pre- and co-seasonal regimen than is initiated before 
the start of the season. However, confirmation of the 
end of a pollen season may be more valuable for high-
lighting the end date for co-seasonal administration.
Allergists are clearly moving towards patient-centered 
care and PSPs, as illustrated by the new MASK-rhinitis 
IT tool (developed as part of the European Innova-
tion Partnership on Active and Healthy Ageing) for 
diagnosing, stratifying and managing patients with AR 
and assessing treatment efficacy [35]. The MASK-rhi-
nitis smartphone application for the patient combines 
e-Allergy screening (for early online diagnosis of allergy 
and asthma), the daily rating of rhinitis symptoms on a 
visual analogue scale and an assessment of disease con-
trol using the control of allergic rhinitis and asthma 
test. It is interfaced with a clinical decision support sys-
tem based on the widely used allergic rhinitis in asthma 
guidelines [36]. With the rapid growth of mobile Internet 
use, smartphone apps are inevitably going to be key com-
ponents of PSPs.
The field of asthma (a condition that is generally but 
not always allergic) may provide valuable insights for 
PSPs in AIT of allergic respiratory diseases. Over the 
last few decades, intense effort has been devoted world-
wide to delivering and promoting asthma education, 
self-management and personal action plans. By way of an 
example, a recent study has shown that self-monitoring, 
individualized asthma action plans, information about 
assessments and correct use of an inhaler do increase 
adherence and provide clinically useful data on disease 
control [37]. In another study, an intervention based on 
a “physician on call patient engagement trial” mobile 
phone application was associated with improvements in 
activity, productivity, disease control, disease perception 
and emotion, although adherence was not assessed [38]. 
However, systematic reviews of this aspect revealed the 
absence of a clear clinical trial-based evidence in favor of 
these asthma interventions. In Coffman et al.’s US-based 
meta-analysis of the effects of pediatric asthma education 
on hospitalizations, emergency department visits, and 
urgent physician visits, 37 trials met the meta-analysis’ 
inclusion criteria [39]. The researchers concluded that 
although pediatric asthma education reduced the mean 
number of hospitalizations and emergency department 
visits and the likelihood of an emergency department 
visit, there was no significant effect on the likelihood of 
hospitalization in general or the mean number of urgent 
physician visits. Similarly, in a meta-analysis of 37 studies, 
Pinnock et  al. [40] concluded that only “whole systems 
approaches” that explicitly and simultaneously addressed 
patient-, professional- and organization-related factors 
were associated with consistent improvements in clini-
cal outcomes in asthma, although adherence per se was 
rarely studies. This approach typically combined (1) 
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direct patient coaching, free resources, patient mentors 
and/or group activities, (2) continuing professional edu-
cation and training for specialists and/or primary care 
physicians, and (3) local and/or national health promo-
tion and awareness programs [40].
A call to action for PSPs in the field of AIT
A number of practical questions and choices must be 
considered when implementing a PSP for AIT. We 
encourage researchers, physicians, other healthcare pro-
fessionals, learned societies, medical associations and 
patient organizations to explore and refine the following 
points.
  • Levels of adherence should be measured as soon 
as a patient has been prescribed AIT and then on a 
regular basis thereafter. Both patients and physicians 
should be able to display data on changes over time 
in adherence and engagement. Validated tools exist, 
such as the 4- or 8-item Morisky Medication Adher-
ence Scale [41]. The PSP interface could also be used 
to assess disease control in allergic rhinitis or asthma 
[42, 43]. Ideally, a PSP should be able to identify par-
ticular barriers to adherence (see Table 1), character-
ize non-adherence profiles (poor dosage vs. poor per-
sistence, for example) and adapt actions and content 
accordingly. For example, a patient suffering from 
forgetfulness could be invited to view a short video 
giving behavioral tips on improving self-organization. 
A PSP should also be able to rapidly detect patients 
with special communication needs.
  • Technological choices Modern technology enables the 
interactive, mass dissemination of customized infor-
mation. However, the application of technology per 
se is not a panacea for engagement and adherence; 
“hi-tech” must be balanced against “hi-touch”—the 
maintenance of a close personal connection. Mistry 
et  al. [44] have stated that there are too few high-
quality studies to reliably assess the effectiveness 
of technology-mediated interventions; of 38 stud-
ies reviewed, 24 did not find significant effects on 
both adherence and clinical outcomes. By way of an 
example, Alesina et  al. [45] recently studied the use 
of an electronic tablet container (the Memozax) with 
a programmable daily sound alarm in 261 patients 
taking a timothy grass pollen sublingual AIT tablet 
in Italy. The patients were randomized 1:1 to use of 
the device or not. After 1  year, the compliance rate 
in the Memozax group was slightly higher (91.7  %) 
than that in the non-Memozax group (90.3  %) but 
this difference was not statistically significant. In 
general, there is a lack of robust, clinical trial data on 
the efficacy of health information technology tools 
in the self-management of respiratory disease. Easy 
access to the Internet and the ease with which apps 
can be created have disadvantages, too; the same 
group’s review of 103 apps for asthma in English 
found that none combined reliable, comprehensive 
patient information with supportive tools for self-
management [46]. In a recent Cochrane Collabora-
tion review, the same group searched for randomized 
controlled trials on the clinical effectiveness, cost-
effectiveness and feasibility of smartphone and tab-
let apps in the self-management of individuals with 
asthma. Only two trials (totaling 408 participants) 
met the inclusion criteria, and neither found a signifi-
cant effect on adherence [47].
  • Reminders, communication channels and content A 
PSP designed to enhance adherence is likely to fea-
ture prominent reminders to take medications, refill 
prescriptions or contact a healthcare professional. 
These reminders may be based on phone calls, text 
messages, e-mail messages, pagers, interactive voice 
response systems, video calls, “smart” electronic 
medication containers, or combinations thereof. 
Furthermore, the use of “push” messaging and social 
networks in a PSP may be confronted with “infor-
mation overload” in which messages are not seen 
or not opened. The optimal frequency of messag-
ing will depend on the disease, the treatment, the 
symptom burden and, of course, the patient’s per-
sonal preference. For example, adherence remind-
ers should probably be issued on a daily basis for 
the at-home administration of SLIT but much less 
frequently for patients receiving SCIT. Another 
question is whether to introduce one technology-
based intervention at a time or several simultane-
ously. A PSP must be able to anticipate and avoid 
“information fatigue” amongst its users. Lastly, 
messaging-based reminders may be unidirectional 
or bidirectional. In the latter situation, participants 
are encouraged to respond to reminders by giving 
information on adherence—even though this is usu-
ally impossible to verify. A smart, responsive sys-
tem that takes account of the patient’s replies and 
redefines the messaging content accordingly may 
be preferable to “dumb”, alarm-clock-like remind-
ers. Whereas poor adherence will generally trigger 
encouraging, advisory reminders, the opposite is 
also valid; congratulatory messages can be used to 
“reward” good compliance.
  • Custom platforms or open social media? Mainstream 
social media platforms are easy to use and extremely 
wide-ranging but may not be sufficiently trusted and 
authenticated to convince and motivate patients. 
Validated, “official” sources of information should be 
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developed in collaboration with patient associations 
and/or medical associations.
  • Age-specific content Elderly adults, young adults, 
teenagers, young children and the latter’s parents 
have differing communication abilities, styles and 
habits. A PSP will have to be capable of using an 
appropriate language style when addressing a par-
ticular age group; communication will be totally dif-
ferent.
  • When in the patient’s journey can or should he/she 
be contacted by the PSP provider? In AIT, it is prob-
ably best to initiate a PSP as soon as the patient has 
been diagnosed with an allergy because understand-
ing the nature of allergic disease is essential for taking 
informed treatment decisions thereafter [48].
  • Interactivity and data validity Should patients be 
able to request meetings or interactions with their 
physician or other health advisors? And if the PSP 
collects patient-reported data, will these data be reli-
able enough to be of use in setting or modifying the 
treatment strategy?
  • The involvement of “patient leaders” It has been 
reported that patients with chronic conditions (heart 
disease, lung disease, stroke, or arthritis) benefit from 
short self-management courses in which they learn 
from other patients [49]. Furthermore, some coun-
tries have “train the trainers” courses for asthma, 
eczema or anaphylaxis; this could be extended to AIT.
  • Caregiver involvement This is essential for pediat-
ric PSPs and even for slightly older populations. For 
example, research in asthma has shown that car-
egiver support for adherence is still important in ado-
lescence and young adulthood, even as these patients 
gain independence in dealing with their illness and 
treatment [50, 51].
Conclusion
Multicomponent, multichannel, multistakeholder PSPs 
are needed to trigger patient engagement, increase 
knowledge about allergic diseases, overcome poor adher-
ence to AIT and, ultimately, improve health outcomes 
through better patient self-management and stronger 
physician-patient partnerships which is of high impor-
tance especially in the field of AIT. By way of an analogy, 
the patient is no longer a mere “passenger”; the patient 
(and not the physician) is sitting in the driver’s seat, and 
the physician’s role is now to act as a guide and a coach. 
AIT providers have an important role to play (whether 
directly or indirectly) in PSPs, with a move towards this 
new paradigm.
The available evidence suggests that approaches with 
system-based reminders alone are not sufficiently effec-
tive on adherence. It would be interesting to design 
clinical trials in which adherence is the primary crite-
rion, evaluating “hi-tech” interventions (based mainly 
on information technology) and “hi-touch” interventions 
(based mainly on interaction with humans, i.e. family 
members, patient mentors and healthcare professionals). 
However, the available evidence suggests that no single 
approach—whether tech- or human-based—has a signifi-
cant, lasting impact on adherence; only “whole systems 
approaches” (combining patient-, provider and society-
based actions) might do so [40].
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